OTI-2024
Glaucoma
Pre-clinicalActive
Key Facts
About Ophthalmic Therapeutic Innovation
Ophthalmic Therapeutic Innovation is a private, preclinical-stage biotech targeting a transformative approach to glaucoma treatment. The company's core asset, OTI-2024, is positioned as a dual-mechanism agent aiming to remove the 'rate-limiting root causes' of glaucoma, potentially moving beyond symptomatic IOP management to disease modification. While promising, the company is at an early stage with a single disclosed asset, facing significant development and competitive risks inherent to novel ophthalmic drug discovery. Its success hinges on validating its unique adenosine/MMP platform and advancing OTI-2024 through clinical trials.
View full company profileTherapeutic Areas
Other Glaucoma Drugs
| Drug | Company | Phase |
|---|---|---|
| PREZIA Glaucoma Implant | PolyActiva | Preclinical |
| MIGS Device System | Micropoint Biotechnologies | Commercial |
| INM-088 | InMed Pharmaceuticals | Preclinical |
| OT-401 | Ocumension Therapeutics | Phase 2 |
| ANX007 | Annexon Biosciences | Phase 2 |
| PER-001 | Perfuse Therapeutics | Phase 2 |
| hOTX2 | BrainEver | Discovery |
| Glaucoma Treatment | BVI Medical | Commercial |
| MediPrint Lens (Glaucoma) | MediPrint Ophthalmics | Phase 2b |
| Glaucoma Program | Broadwing Bio | Pre-clinical |
| MSC Exosomal Eye Serum | Vitti Labs | Pre-clinical |
| BTQ1902 | Betaliq | Phase 2 |